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Background: Prior to diagnosis, patients with haematological cancers often have multiple primary care consultations,
resulting in diagnostic delay. They are less likely to be referred urgently to hospital and often present as emergencies.
We examined patient perspectives of time to help-seeking and diagnosis, as well as associated symptoms and
experiences.
Methods: The UK’s Haematological Malignancy Research Network (www.hmrn.org) routinely collects data on all
patients newly diagnosed with myeloma, lymphoma and leukaemia (>2000 annually; population 3.6 million).
With clinical agreement, patients are also invited to participate in an on-going survey about the circumstances
leading to their diagnosis (presence/absence of symptoms; type of symptom(s) and date(s) of onset; date medical
advice first sought (help-seeking); summary of important experiences in the time before diagnosis). From 2004–2011,
8858 patients were approached and 5038 agreed they could be contacted for research purposes; 3329 requested and
returned a completed questionnaire. The duration of the total interval (symptom onset to diagnosis), patient interval
(symptom onset to help-seeking) and diagnostic interval (help-seeking to diagnosis) was examined by patient
characteristics and diagnosis. Type and frequency of symptoms were examined collectively, by diagnosis and
compared to UK Referral Guidelines.
Results: Around one-third of patients were asymptomatic at diagnosis. In those with symptoms, the median patient
interval tended to be shorter than the diagnostic interval across most diseases. Intervals varied markedly by diagnosis:
acute myeloid leukaemia being 41 days (Interquartile range (IQR) 17–85), diffuse large B-cell lymphoma 98 days (IQR
53–192) and myeloma 163 days (IQR 84–306). Many symptoms corresponded to those cited in UK Referral Guidelines,
but some were rarely reported (e.g. pain on drinking alcohol). By contrast others, absent from the guidance, were more
frequent (e.g. stomach and bowel problems). Symptoms such as tiredness and pain were common across all diseases,
although some specificity was evident by sub-type, such as lymphadenopathy in lymphoma and bleeding and
bruising in acute leukaemia.
Conclusions: Pathways to diagnosis are varied and can be unacceptably prolonged, particularly for myeloma and
some lymphomas. More evidence is needed, along with interventions to reduce time-to-diagnosis, such as public
education campaigns and GP decision-making aids, as well as refinement of existing Referral Guidelines.
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In comparison to many other cancers, the pathway to
diagnosis of haematological malignancies (leukaemias,
lymphomas and myeloma) can be fraught with difficulty,
and is often associated with excessive time between symp-
tom onset, help-seeking and diagnosis; multiple primary
care consultations before referral to secondary care; and
an increased chance of being diagnosed after emergency
admission [1-17]. Diagnostic delay is considered to increase
complications in patients with some haematological ma-
lignancies [8], and a recent review specifically identified
these as diseases for which early diagnosis could improve
outcome [18]. In Great Britain a recent study estimated that
around 3500 deaths occurring within five years of diagnosis
of a haematological malignancy could be avoided if survival
matched that of the rest of Europe [19].
Haematological malignancies comprise a heterogeneous
group of over 60 cancer sub-types, many of which have
unique clinical pathways and outcomes [20]. As a group
these cancers are relatively common, accounting for around
one in ten of all new cancer diagnoses in the developed
world [21,22]. However, unlike some cancers, their clinical
presentation is recognised as being broad and ill-defined,
particularly in terms of initial symptoms; which may be
non-specific, difficult to differentiate from those of benign,
self-limiting conditions, and associated with a long pro-
drome [2,7]. Early diagnosis of haematological malignancies
therefore poses exacting challenges for patients and
clinicians; patients must determine when to seek help and,
when they do, practitioners must identify the symptoms
of potential malignancy and make appropriate and timely
referrals to secondary care.
Ensuring early diagnosis of all cancers, including haem-
atological malignancies, has been a key priority for the UK
Department of Health for over a decade [23-27]. Initiatives
such as the production of Referral Guidelines for Suspected
Cancer to help general practitioners (GPs) identify cancer
symptoms early, and waiting-time targets to ensure rapid
diagnosis and treatment, are now firmly embedded in
primary and secondary healthcare systems [28]. In terms
of haematological malignancies, a single list of symptoms
has been developed to guide GPs in their identification of
patients with constellations of these, which may indicate
potential disease. Existing evidence about symptoms of
haematological malignancies, however, has been largely
derived from expert committee reports [28] or from
studies that have focused on pre-determined symptoms
or clinical parameters (blood and other diagnostic test
results) [9,10,29-31]; although several often smaller
studies do exist that have examined complete symptom
profiles [7,8,11,12,32-35]. The aim of this study was to
examine time to help-seeking and diagnosis of haemato-
logical malignancies, as well as associated symptoms, from
the patient perspective.Methods
Covering a population of 3.6 million that is broadly repre-
sentative of the UK as a whole, this study was conducted
within the robust infrastructure of the Haematological
Malignancy Research Network’s (www.hmrn.org) on-going
patient cohort [36,37]. Established in 2004, HMRN is a
collaboration between the clinical haematology network,
researchers at the University of York and the Haemato-
logical Malignancy Diagnostic Service (www.hmds.info),
which diagnoses all haematological malignancies in the
area coding to the latest WHO classification scheme [20].
More than 2000 patients are registered annually and
demographic, prognostic and treatment data are routinely
abstracted from their medical records. HMRN has full
ethical approval and Section 251 exemption to collect data
for audit and research purposes.
In addition, and with permission from their clinical
teams, patients are asked to consent to being approached
in the future for further research purposes. Reflecting the
diversity of disease sub-types, different consenting strategies
are used (face-to-face for in-patients, postal for out-patients
etc.). At this time, patients (≥ 18 years) are also given an
information leaflet inviting them to take part in our on-
going survey about symptoms and help-seeking. Those
that agree are sent a questionnaire asking: ‘Did you have
any symptoms before you were diagnosed with your present
illness?’ to which the response is documented by ticking
‘Yes’ or ‘No’. People that tick ‘Yes’ are asked to list all their
symptom(s) during this time and the exact (or if not ap-
proximate) date of onset of each. Finally, patients are asked
to provide the date that medical advice was first sought
(help-seeking) for any of the symptoms that they have
listed. To avoid leading questions patients’ report in
free-text, using their own words and phrases, rather than
ticking pre-selected symptoms. We do not ask that symp-
toms reported are limited to those that the patients are
sure relate only to their haematological malignancy; this is
because of the difficulties inherent in such decisions.
Importantly, the questionnaire also contains a text box in
which patients can tell us anything else they consider
important in relation to their disease pathway.
This report summarises information on time to help-
seeking and diagnosis, as well as symptoms, collected over
seven years, 2004–11. Three time intervals were examined
in symptomatic patients; the total interval (from date of
first symptom onset to diagnosis); the patient interval
(from date of first symptom onset to first help-seeking);
and the diagnostic interval (from date of first help-seeking
to diagnosis and including the time when the patient’s care
is being managed in primary and/or secondary care) [38].
These data are examined by patient characteristics and
diagnosis and are presented as medians and interquartile
ranges (IQRs). Symptoms are examined in total and by
diagnostic group and findings compared to those cited
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ducted using Stata version 12 [39] and standard descrip-
tive methods were applied. Finally, information reported
in the free text box of the questionnaire by individuals
about their diagnostic experiences was studied in detail;
examples were then drawn together for illustrative pur-
poses, in order to highlight the variations and difficulties
inherent in this process.
Results
During the seven year period September 2004 to August
2011, 5038 (57%) of the 8858 patients approached agreed
to be contacted again, and 3329 (66% of the 5038, 38%
of the 8858) requested and returned a completed ques-
tionnaire (Table 1). No marked demographic or diagnostic
differences were observed between subjects who agreed to
complete a questionnaire and those who did not.
Just over two-thirds (2336) of the 3329 patients who
returned a completed questionnaire reported that they had
one or more symptoms before diagnosis. The diagnostic
categories listed in Table 1 are ordered according to the
absolute numbers of patients reporting symptoms; ranging
from 451 with diffuse large B-cell lymphoma through to
six with Burkitt lymphoma. The likelihood of experiencing
symptoms varied markedly by disease sub-type, as can be
seen from Table 1, with around half of patients with some
of the more slowly progressing conditions, such as chronic
lymphocytic leukaemia and myeloproliferative neoplasms,
being asymptomatic at diagnosis (52.8% and 47.7% re-
spectively). In contrast, nearly all patients with more ag-
gressive diseases, such as diffuse large B-cell and Hodgkin
lymphoma reported symptoms (89.7% and 86.5% respect-
ively). Indeed, many asymptomatic patients with chronic
lymphocytic leukaemia reported being diagnosed inciden-
tally via blood tests at routine health checks, or check-ups
for other comorbidities, rather than presenting with symp-
tomatic disease.
In symptomatic patients, differences in time to help-
seeking and diagnosis were observed by sex and age.
Among those with symptoms, women had, on average,
longer intervals than men, and those aged ≥80 years
tended to have longer total intervals (symptom onset to
diagnosis) than younger patients and this was largely
driven by the length of the diagnostic interval (help-seeking
to diagnosis). As with the occurrence of symptoms, there
is marked variation in the duration of intervals by diagnosis
(Table 1). As might be expected, the total interval was
shortest for acute myeloid leukaemia at 41 days (inter-
quartile range (IQR) 17–85). The lymphomas tended to
have longer intervals with the more aggressive diffuse
large B-cell lymphoma being diagnosed soonest at 98 days
(IQR 53–192) and marginal zone (generally the most
indolent) having the greatest delay at 172 days (IQR
77–385). The total interval for myeloma was also prolongedat 163 days (IQR 84–306) and myeloproliferative neo-
plasms, again being particularly indolent, were found to
have the longest overall time-to-diagnosis at 215 days
(IQR 84–539). For the vast majority of conditions the
average patient interval (symptom onset to help-seeking)
was considerably shorter than the diagnostic interval. The
main exceptions to this were chronic myeloid leukaemia,
where the patient and diagnostic intervals were 33.5 days
(IQR 4.5-127.5) and 9 days (IQR 5–52) respectively and
acute myeloid leukaemia, being 13 days (IQR 1–47) and
10 days (IQR 5–32) respectively. In contrast, for diffuse
large B-cell lymphoma, the most common of the lymph-
omas, the diagnostic interval accounted for an extremely
large proportion of the time-to-diagnosis, having a patient
interval of 9 days (IQR 1–42) and diagnostic interval of
69 days (IQR 37–134).
Information on symptom frequency across all haemato-
logical malignancies combined is presented in Figure 1. In
line with UK Referral Guidelines (blue bars), symptoms
most frequently reported were tiredness, pain, lump, short-
ness of breath/cough, skin problems, abnormal sweating
and infections. However, certain listed symptoms were
mentioned comparatively infrequently, most notably pain
when drinking alcohol, which was only reported by five
patients – all with lymphoma. By contrast, as can be seen
from Figure 1 (red bars), patients identified a range of
other symptoms, including for example, stomach/bowel
problems, joint problems and fractures, cardiovascular
problems, dizziness and loss of appetite. No differences
were detected in time-to-diagnosis between those that re-
ported having symptoms cited in the UK Referral Guide-
lines and those that did not (data not shown).
A number of the reported symptoms, such as tiredness
and pain, occurred across all diseases (Figure 2). The type
of pain reported varied, however, by diagnosis, with muscu-
loskeletal pain being particularly pronounced in myeloma,
abdominal pain being common in the non-Hodgkin
lymphomas and chest pain in patients with acute leukaemia
and myelodysplastic syndrome (data not shown). Further-
more, in contrast to traditional perceptions of painless
lymphadenopathy, some patients reported otherwise, par-
ticularly for Hodgkin lymphoma. For other symptoms
there was greater specificity by sub-type: bruising/bleeding
and shortness of breath/cough in acute myeloid leukaemia
and myelodysplastic syndromes; lymphadenopathy (usually
reported as a lump) in lymphoma; joint problems and frac-
tures in myeloma. However, with around half of all patients
only reporting one symptom, there were no obvious con-
stellations by diagnostic group (data not shown). We were
unable to match any of the reported symptoms with any of
those in the Referral Guidelines in 10% of patients, and this
was most common in patients with myeloproliferative neo-
plasms. In addition to skin problems (which are included
in the Referral Guidelines) patients with myeloproliferative







Symptoms N (%) Interval - Median Days (25–75 percentile – interquartile range)
No Yes Total2 Patient3 Diagnostic4
Total 8858 (100) 5038 (100) 3329 (100) 993(29.8) 2336 (70.2) 123 (55–277) 17 (1–86.5) 65 (26–155)
Sex:
Males 4938 (55.7) 2840 (56.4) 1865 (56) 617 (33.1) 1248 (66.9) 108 (52–252) 16 (1–75) 62 (24–152)
Females 3920 (44.3) 2198 (43.6) 1464 (44) 376 (25.7) 1088 (74.3) 138 (62–315) 26 (1–91) 72 (29–158)
Age at diagnosis (years):
Median age (Range) 69.2 (18.1-99.7) 67.7 (18.1-96.8) 67.4 (18.1-95.2) 66.3 (18.1-95.2) 69.9 (19.2-94.7) - - -
< 40 664 (7.5) 330 (6.6) 216 (6.5) 25 (11.6) 191 (88.4) 120.5 (47–251) 23.5 (1–92) 55.5 (20–137)
40-59 1821 (20.6) 1138 (22.6) 773 (23.2) 178 (23.0) 595 (77.0) 124 (59–258) 30 (1–85) 64 (27–144)
60-69 2087 (23.6) 1362 (27) 921 (27.7) 295 (32.0) 626 (68.0) 119.5 (56–269) 17 (1–91) 67 (26–167)
70-79 2701 (30.5) 1506 (29.9) 1018 (30.6) 350 (34.4) 668 (65.6) 122 (57–311.5) 16 (1–74) 66 (27–142.5)
80+ 1585 (17.9) 702 (13.9) 401 (12) 145 (36.2) 256 (63.8) 139 (48–354) 16 (1–78) 73 (28–189)
Diagnostic group1:
Diffuse large B-cell lymphoma 1342 (15.2) 771 (15.3) 503 (15.1) 52 (10.3) 451 (89.7) 98 (53–192) 9 (1–42) 69 (37–134)
Myeloma 1263 (14.3) 755 (15) 493 (14.8) 152 (30.8) 341 (69.2) 163 (84–306) 31 (1–122) 83 (34–167)
Follicular lymphoma 660 (7.5) 413 (8.2) 284 (8.5) 51 (18.0) 233 (82.0) 112 (61–250) 17 (1–76) 65 (36–125.5)
Myeloproliferative neoplasms 1183 (13.4) 674 (13.4) 430 (12.9) 205 (47.7) 225 (52.3) 215 (84–539) 31 (1–168) 77 (27–239)
Marginal zone lymphoma 616 (7) 384 (7.6) 247 (7.4) 68 (27.5) 179 (72.5) 172 (77–385) 30 (1–153) 86.5 (27–193.5)
Myelodysplastic syndromes 720 (8.1) 424 (8.4) 267 (8) 97 (36.3) 170 (63.7) 147 (55–393) 16 (1–89) 88 (24–249)
Hodgkin lymphoma 574 (6.5) 292 (5.8) 193 (5.8) 26 (13.5) 167 (86.5) 158 (84–288) 30 (2–77) 87 (40–166)
Chronic lymphocytic leukaemia 650 (7.3) 344 (6.8) 265 (8) 140 (52.8) 125 (47.2) 86 (38–238) 22 (1–85) 42 (12–88)
Acute myeloid leukaemia 538 (6.1) 249 (4.9) 161 (4.8) 37 (23.0) 124 (77.0) 41 (17–85) 13 (1–47) 10 (5–32)
Chronic myeloid leukaemia 207 (2.3) 143 (2.8) 95 (2.9) 28 (29.5) 67 (70.5) 96 (32–169) 33.5 (4.5-127.5) 9 (5–52)
Mantle cell lymphoma 159 (1.8) 96 (1.9) 65 (2) 13 (20.0) 52 (80.0) 104 (58–258) 21.5 (1–69.5) 61 (29–144)
Lymphoproliferative disorder NOS 322 (3.6) 153 (3) 97 (2.9) 53 (54.6) 44 (45.4) 324 (48–578) 16 (1–30) 185 (27–417)
T-cell lymphoma 148 (1.7) 72 (1.4) 52 (1.6) 10 (19.2) 42 (80.8) 175 (70–306) 18.5 (1–92) 71 (39–167)
Acute lymphoblastic leukaemia 96 (1.1) 50 (1) 37 (1.1) 8 (21.6) 29 (78.4) 32.5 (17–64) 16 (2–26) 12.5 (3–32)
Myelofibrosis 91 (1) 54 (1.1) 35 (1.1) 12 (34.3) 23 (65.7) 314 (76–742) 5 (1–66) 93 (25–320)
Myelodysplastic/Myeloproliferative neoplasms 125 (1.4) 66 (1.3) 41 (1.2) 18 (43.9) 23 (56.1) 421 (139–709) 31 (16–308) 128 (27–840)
T-cell leukaemia 62 (0.7) 37 (0.7) 32 (1) 13 (40.6) 19 (59.4) 502 (75–761) 30 (3–153) 61 (37–367)
Hairy cell leukaemia 65 (0.7) 43 (0.9) 26 (0.8) 10 (38.5) 16 (61.5) 88.5 (44–194) 35 (1–138) 16 (10–32)
Burkitt lymphoma 37 (0.4) 18 (0.4) 6 (0.2) 0 (0.0) 6 (100.0) 67.5 (34–136) 19 (4.5-30.5) 36 (11–82.5)













































Figure 1 Distribution of symptoms. All symptoms are coded once only. Pain: includes musculoskeletal, abdominal, chest and other; Infections:
include throat, chest, common cold, flu (like symptoms), mouth sores, skin infections and other; Stomach/bowel: nausea, vomiting, bloated,
indigestion, diarrhoea and other; Bruising/bleeding: includes nosebleeds, bleeding from bowel/stomach, gums/mouth and other; Cardiovascular:
includes abnormal blood pressure, abnormal heart beat, stroke, deep vein thrombosis and other.
















Tiredness Pain Lump Short of breath/cough
Itching/rash Abnormal sweating Infections Stomach/bowel
Weight loss Bleeding/bruising Joint problems/fractures Cardiovascular
Dizzy/faint Headaches Loss of appetite Other
Figure 2 Distribution of symptoms by diagnostic group.
Howell et al. BMC Hematology 2013, 13:9 Page 5 of 9
http://biomedcentral.com/2052-1839/13/9
Howell et al. BMC Hematology 2013, 13:9 Page 6 of 9
http://biomedcentral.com/2052-1839/13/9neoplasms were most likely to report headaches, cardiovas-
cular problems and feeling dizzy/faint (none of which are
included in the Guidelines).
The challenges and variations associated with diagnosing
haematological cancers, particularly myeloma and lymph-
oma, are clear from the List of self-reported experiences
presented, which have been drawn together for illustrative
purposes. These accounts range from patients acknowledg-
ing that they were diagnosed incidentally after a routine
blood test, without experiencing any symptoms, to those
reporting particularly poor experiences in terms of multiple
symptoms, repeated consultations, emergency presentation
and prolonged time-to-diagnosis. A wide variety of reasons
for delayed help-seeking are highlighted in these excerpts
including: musculoskeletal pain on a background of exist-
ing bone/joint problems; having an abnormal lump with
no pain; and having symptoms which were intermittent.
However, poorer experiences did not always correlate with
longer time-to-diagnosis; and some patients were diag-
nosed quickly, but reported being acutely ill and repeatedly
consulting GPs or presenting in emergency departments
during this time.
List of self-reported experiences
Diffuse large B-cell lymphoma, aged 30–40 years
Symptoms: Pain in left shoulder and left side of chest,
not able to lie down, tiredness, breathlessness, cough,
weight loss, coughing up blood.
Free text: “Went to the doctors at least 8 times. Kept
telling me it would not be anything serious as I was too
young. I demanded an x-ray in (month) as symptoms
kept getting worse.”
Interval: Patient (i.e. symptom onset – help-seeking) -
immediate; diagnostic (i.e. help-seeking – diagnosis) -
5 months.
Diffuse large B-cell lymphoma, aged 70–80 years
Symptoms: Tiredness, lump in neck.
Free text: “Initially, the lump appeared and disappeared
gradually getting bigger and harder each time. There was
no pain or discomfort associated with it at any time.”
Interval: Patient - 3 months; diagnostic - 2 months.
Myeloma, aged 50–60 years
Symptoms: Aches in bones/joints, general mood change.
Free text: “I think most of the time my doctor at doctors
thought I was just a hypochondriac and putting it on as I
suffer from long term post-traumatic stress disorder.”
Interval: Total (i.e. symptom onset – help-seeking) -
1 year.
Myeloma, aged 60–70 years
Symptoms: Backache, tiredness, poor skin and hair.
Free text: “I had two hip replacements in the past. I
assumed that the backache in (month) was due to
something wrong with these. I was prescribed (drug)and later (drug). My doctor sent me for a hip x-ray at
the hospital only after the physio I was seeing asked
(doctor) directly. This came back with no problem with
the hips. As regards the backache, this just got worse
and worse and still no referral to an ortho was arranged
until I had reached rock bottom physically and men-
tally. The ortho blood tests revealed high calcium levels
and I was admitted as an emergency (month).”
Interval: Patient - 1 month; diagnostic - 1 year.
Myeloproliferative neoplasm, aged 30–40 years
Symptoms: Itchiness (mainly legs, also arms, back and
chest), red/brown speckles on toes and ankles, migraine.
Free text: “Although I was aware of the symptoms for
some time I had put them down to other potential
causes e.g. itchiness seemed to follow certain foods,
speckles on toes/ankles looked like freckles, migraines
came when tired following busy periods at work and
more recently (date and event) when I also felt faint at
work on a couple of occasions when particularly tired.
The itchiness had become more regular and more
severe in that I was unable to sleep on some nights
(which could be several nights in a row) obviously
adding to the tiredness. However, the symptoms were
more of an inconvenience that a particular worry and I
didn’t specifically seek medical advice. I just mentioned
them when visiting the doctor for an unrelated knee
pain. The subsequent blood test (in light of the
speckles) uncovered the blood disorder.”
Interval: Patient - 18 months; diagnostic – 1 year.
Myeloproliferative neoplasm, aged 60–70
Symptoms: None reported.
Free text: “I didn’t seek medical help for my blood
disorder – it was detected through the regular blood
tests which I have as part of the monitoring of my
diabetes.”
Interval: Incidental finding – no delay.
Acute myeloid leukaemia, aged 40–50 years
Symptoms: Lower back ache, unexplained bruises,
feeling weak and tired.
Free text: “On (date), the day I first went to the Doctors,
I was able to carry out my normal daily duties e.g.
shopping, walking about, cleaning etc. The only reason I
went to the Doctors was because of a few unexplained
bruises. I had a period at the time which was a lot heavier
than my normal ones. This got worse throughout the
week, so I think I would have noticed something was
wrong had I not already been to the doctors. I was
admitted to hospital (day after help-seeking).”
Interval: Patient – 2 months; diagnostic – 1 day.Discussion
This paper presents results from a study examining self-
reported time to help-seeking and diagnosis, as well as
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logical cancers. Substantial variation was noted in the
experiences reported by patients and this was largely
driven by diagnostic sub-type. This is because sub-type
generally determines disease aggressiveness, the manifest-
ation of symptom(s) and the speed with which these
exacerbate. Thus time-to-diagnosis was shortest for
acute myeloid leukaemia, which is generally perceived as
the most aggressive, acute and rapidly progressive disease,
longer for the lymphomas and particularly prolonged for
myeloma. The large number of patients without any
symptoms (30% overall, rising to around half in particu-
larly indolent conditions) often reported that they had
been diagnosed incidentally when blood tests were taken
to monitor other comorbidities or at routine health checks
carried out at GP surgeries. In this respect, the diagnostic
sub-types of those less likely to experience symptoms
in our study correspond with the diseases that can be
identified by blood testing alone (e.g. chronic lymphocytic
leukaemia and myeloproliferative neoplasms).
A myriad of different symptoms were reported and
although some, such as tiredness and pain, were common
across diseases, there was some specificity by sub-type.
Tiredness, perhaps occurring as a consequence of anaemia
was expected, however, the frequency with which pain
was reported was surprising and it is possible that pain
may have been previously underestimated. Although many
of the symptoms reported corresponded to those cited
in UK Referral Guidelines for Suspected Cancer [28] a
number of these were rarely mentioned by patients while
others were frequently reported, but absent from the
Guidelines. Interestingly, only five lymphoma patients
reported pain after drinking alcohol.
Strengths and weaknesses
As far as we can identify, this is the largest and most
comprehensive study asking patients across all sub-types
of haematological cancers (nineteen distinct diagnostic
categories in total) to report their symptoms and help-
seeking experiences before diagnosis. In order to limit
recall bias, data were collected soon after diagnosis, with
questionnaires generally being dispatched within 6 weeks
of diagnosis. HMRN was established in order to facilitate
research with patients and as our study was predicated on
this infrastructure, we had access to a large population-
based cohort of patients that had already consented to
being approached for research purposes. HMRN includes
patients of all ages and with all haematological malignan-
cies, classified according to WHO schema [20], meaning
that we were able to examine and compare symptoms and
time-to-diagnosis across all disease sub-types, some of
which had not previously been examined. Patients are
asked to consent to being approached for future HMRN
research with permission from their clinical team;unfortunately, some patients are deemed too ill to be
approached, and others die soon after diagnosis. Conse-
quently, the experiences of patients with very acute/ag-
gressive or advanced stage disease (perhaps as a
consequence of longer time-to-diagnosis) may not have
been included in our study.
It was our intention to capture the breadth of symptoms
patients considered to be related to their diagnosis;
however, there are always uncertainties inherent in using
self-reported data and variation may have occurred in the
completeness with which patients reported their symp-
toms – some recording them all and others only reporting
those most troublesome or painful. Use of self-reported
data may also be limited by the patient’s ability to distin-
guish symptoms of haematological cancer from those
that are unrelated, particularly at older ages when comor-
bidities are likely to be more common. Nonetheless it is
important to take account of the patients’ interpretation
of their own experiences. We are currently building on
these data, however, by examining symptoms, symptom
management, visit frequency and referral pathways in
primary and secondary medical records, with funding
from the National Awareness and Early Diagnosis Initiative
[27]. Although using data from medical records has its
own disadvantages, this will provide further evidence and
also enable us to explore the diagnostic interval in greater
detail.
Comparison of findings with previous literature
Few studies, with the exception of those that are qualitative,
have previously collected self-reported symptom-data, and
ours is the largest to do this. Using this approach meant
that patients could tell us their interpretation of events
leading to diagnosis, and the symptoms they considered
to be related to their disease. Comparing findings about
time-to-diagnosis is always difficult due to different methods
of data collection (self-reported survey, medical records,
medical insurance claim dates), use of different summary
measures (mean or median) and variation in the time-
periods calculated [38]. Existing studies vary in size, with
larger North American studies using SEER/Medicare data
based on claims for specific symptoms [9,10]. However,
average time-to-diagnosis of lymphoma (multiple types) in
existing studies was reported at between 2.5 months and
around a year [1,4,5,40,41]; myeloma was between 3 and
5.5 and a half months [9,29]; chronic lymphocytic leukae-
mia 3 months [10]; and chronic myeloid leukaemia 5
months [11]. Findings from our study are similar to these,
with the exception of chronic myeloid leukaemia, which
we found to be somewhat shorter at around 3 months.
Unlike existing studies, we collected information about
all symptoms, rather than pre-defining the categories which
would be included. Close correlation was, however, identi-
fied between the major symptoms we reported and those
Howell et al. BMC Hematology 2013, 13:9 Page 8 of 9
http://biomedcentral.com/2052-1839/13/9in existing research studies of lymphoma [7,32,35], mye-
loma [8,12,34], chronic myeloid leukaemia [11,33] and
chronic lymphocytic leukaemia [10], although we were
able to identify a far wider range.
Implications of the study
This study provides clear evidence that time-to-diagnosis of
haematological malignancies, notably myeloma and some
lymphomas, can be unacceptably prolonged. The pathway
to diagnosis of these cancers is reported to be more likely
to include strings of repeat GP consultations [17], which
are associated with a prolonged interval before hospital
referral [15]; infrequent use of the urgent referral route
(suggesting that malignancy is not suspected at referral)
and frequent emergency presentation prior to diagnosis
[16]. Previous studies of lymphoma also indicate that pa-
tients are rarely referred directly to haematology by GPs [6].
Diagnosing these diseases is undoubtedly fraught with
difficulty. Symptoms are often vague and frequently seen
in primary care in patients with non-malignant illness,
making it difficult to differentiate patients that need urgent
hospital referral from those that do not. Lack of knowledge
about the symptoms of lymphoma among patients, as well
as the particular characteristics of these symptoms (e.g.
potentially painless, intermittent lumps) have also been
reported as factors acting as barriers to help-seeking [7].
Importantly, unlike many other cancers (e.g. breast,
testicular, prostate, melanoma) the symptom signature
for these diseases is relatively poor; there is no single,
specific symptom to prompt early help-seeking and refer-
ral. Although certain sub-types can be identified by means
of a routine blood test, a specific screening test does not yet
exist. In terms of UK Referral Guidelines, we have shown
that these are not as useful in the context of haematological
malignancy as they may be for other cancers. These factors
are combined with a lack of knowledge about the impact of
delayed diagnosis on outcome in these diseases, although it
is recognised that patients presenting as emergencies have
poorer survival than those presenting via other routes [16].
Despite the difficulties described above, however, it is
important that haematological cancers are diagnosed as
soon as possible, in order both to improve the patient
experience and avoid increasing complications at diagnosis
(such as anaemia, bone disease and renal failure in
myeloma) [8]. Recent initiatives such as the UKs ‘Be
Clear on Cancer’ campaign have been introduced to in-
crease knowledge of the symptoms of certain cancers
among the general public. Similar approaches could be
effective in the context of haematological cancers, describ-
ing for example some of the more disease specific symp-
toms such as the characteristics of lymphadenopathy and
drenching sweats in lymphoma and bleeding and bruising
in leukaemia. Further refinement of the UK Referral
Guidelines for Suspected Cancer (at the very leastdistinguishing between myeloma, lymphoma, and the
acute and chronic leukaemias) could assist GPs to iden-
tify these diseases earlier and make more timely refer-
rals. The introduction of decision aid tools, combining
information on symptoms with that of visit frequency,
particularly with the same or related symptoms, may
also facilitate GP decision-making.
Unfortunately, haematological malignancies are often
overlooked in the context of introducing measures to pro-
mote early diagnosis. However, the findings presented in
this report provide evidence that time-to-diagnosis can be
unacceptably prolonged in these diseases and interventions
are urgently needed to address this issue.
Conclusion
Pathways to diagnosis are varied and can be unacceptably
prolonged, particularly for myeloma and some of the
lymphomas. More evidence is needed, along with interven-
tions to reduce time-to-diagnosis, such as public education
campaigns and GP decision-making aids, as well as refine-
ment of existing Referral Guidelines.
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